Median arcuate ligament syndrome (MALS) is a clinical condition resulting from compression of the abdominal aorta by the median arcuate ligament, leading to narrowing of the lumen of the celiac trunk or mesenteric vessels. This condition is more often observed in young, active patients, often with a female predominance. Clinical manifestations can vary from mild dyspepsia to significant abdominal pain, which complicates diagnosis and leads to frequent surgical interventions. Symptoms may develop due to vasoregulatory disorders, as well as mechanical compression, affecting hemodynamics and oxygen delivery to organs.
History of the disease and interesting historical facts
Median arcuate ligament syndrome was first described in the medical literature in the mid-20th century. However, historically, elements similar to this condition have been mentioned before. In 1965, surgeons A. Katsini and R. Kaplan proposed the term "median arcuate ligament syndrome" to describe this clinical syndrome. Interestingly, before this publication, many cases that could be classified as MALS were misdiagnosed as other gastrointestinal pathologies, indicating the need for further research and understanding of this syndrome.
Epidemiology
The incidence of median arcuate ligament syndrome is relatively low, but in young adults it accounts for approximately 2-5% of all diagnosed cases of abdominal pain. According to examinations in specialized clinics, this syndrome is most often detected in women, and the ratio of women to men is approximately 3:1. Recent studies indicate that there has been an increase in the number of MALS diagnoses over the past two decades, which may be due to increased awareness and the use of modern diagnostic techniques.
Genetic predisposition to this disease
At present, the genetic mechanisms underlying median arcuate ligament syndrome remain a subject of research. It is assumed that certain mutations and polymorphisms affecting receptors involved in metabolism and hemodynamics may predispose a patient to this condition. In particular, some genes associated with collagen metabolism disorders have been identified, which may contribute to the disease picture. However, definitive data on specific genes and mutations directly causing MALS are still lacking.
Risk factors for the development of this disease
There are several risk factors that contribute to the development of median arcuate ligament syndrome. These include:
- Anatomical features: patients with tall stature or high muscle mass are more prone to this syndrome.
- Physical factors: Strenuous physical activity and trauma to the abdominal area may serve as predisposing factors.
- Chemicals: Certain drugs or intoxications can disrupt the body's enzymatic processes.
- Other conditions: Having excess abdominal fat or inflammatory diseases can make MALS worse.
Diagnosis of this disease
Clinical symptoms of median arcuate ligament syndrome are quite varied and may include:
- Pain in the upper abdomen that intensifies after eating.
- Nausea and vomiting.
- Weight loss.
- Fatigue.
The following methods are used to diagnose MALS:
- Laboratory tests: complete blood count, biochemical parameters, determination of creatinine and electrolyte levels.
- Radiological examinations: ultrasound, computed tomography with contrast and angiography.
- Other diagnostic tests: endoscopy and manometry can be used to rule out other possible pathologies.
Differential diagnosis includes diseases accompanied by similar symptoms, such as irritable bowel syndrome, peptic ulcer disease and acute cholecystitis.
Treatment
Treatment of median arcuate ligament syndrome is a multidisciplinary process and may include:
- General treatment: dietary prescription, physiotherapy and individual rehabilitation.
- Pharmacological treatment: anti-inflammatory drugs, analgesics and prokinetics.
- Surgical treatment: Vascular decompression using laparoscopy or open surgery may be indicated in severe cases.
- Other treatments: Psychotherapy and alternative methods (acupuncture) can be used to improve quality of life.
List of medications used to treat this disease
The main medications used to treat MALS include:
- NSAIDs: ibuprofen, naproxen.
- Antispasmodic drugs: mebeverine, prontop.
- Drugs to improve peristalsis: metoclopramide.
Disease monitoring
Monitoring of patients with median arcuate ligament syndrome includes regular follow-up examinations to monitor the dynamics of the condition. The prognosis with early diagnosis and proper treatment is generally favorable, although relapses may occur. Complications may include chronic pain, digestive disorders, and the need for repeated surgical interventions.
Age-related features of the disease
Median arcuate ligament syndrome is most common in the younger age group, mainly between 20 and 40 years. In older people, symptoms may be less pronounced and may be masked by other diseases, which makes diagnosis difficult. In childhood, MALS is quite rare, but individual cases have been described that have confirmed the presence of the disease in children.
Questions and Answers
- How is median arcuate ligament syndrome diagnosed? Diagnosis includes angiography, ultrasound, and assessment of the patient's symptoms.
- What are the main symptoms of MALS? The main symptoms include abdominal pain, especially after eating, as well as nausea and weight loss.
- What is the treatment for MALS? Treatment may include diet, medication, and surgery, depending on the severity of the disease.
- What are the consequences and prognosis for patients with MALS? With adequate treatment, the prognosis is favorable in most cases, but relapses are possible.
- Is there a connection between MALS and other diseases? Yes, MALS can be combined with other gastrointestinal disorders, which requires a comprehensive approach to diagnosis and treatment.
